Current use of PSMA-PET in prostate cancer management (Q38744524)

6 September 2017

Current use of PSMA-PET in prostate cancer management (English)

1 reference

6 September 2017

1 reference

1

1 reference

6 September 2017

Matthias Eiber

2

1 reference

6 September 2017

Markus Schwaiger

series ordinal

3

1 reference

6 September 2017

Jürgen E Gschwend

series ordinal

4

1 reference

6 September 2017

language of work or name

English

0 references

publication date

23 February 2016

1 reference

6 September 2017

Nature Reviews Urology

1 reference

6 September 2017

13

1 reference

6 September 2017

226-235

1 reference

6 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2016.26

6 September 2017

0 references

cites work

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

ESUR prostate MR guidelines 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Prostate-specific membrane antigen: evidence for the existence of a second related human gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Pathological and molecular aspects of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Prostate adenocarcinoma presenting with inguinal lymphadenopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

In vivo visualization of prostate-specific membrane antigen in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Degradation of halogenated aromatic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Characterization of the enzymatic activity of PSM: comparison with brain NAALADase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure–activity relationship studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

PET imaging in prostate cancer: focus on prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The renaissance of the ⁶⁸Ge/⁶⁸Ga radionuclide generator initiates new developments in ⁶⁸Ga radiopharmaceutical chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

PET/MR in prostate cancer: technical aspects and potential diagnostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Multimodal image-guided prostate fusion biopsy based on automatic deformable registration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Comparison between malignant and benign abdominal lymph nodes on diffusion-weighted imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

[11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Early salvage radiotherapy following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

The timing of salvage radiotherapy after radical prostatectomy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Imaging of prostate cancer local recurrences: why and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

11C-choline PET/CT and PSA kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

[(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Dynamic Contrast-enhanced–magnetic Resonance Imaging Evaluation of Intraprostatic Prostate Cancer: Correlation with Radical Prostatectomy Specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Experience with carbon-11 choline positron emission tomography in prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2016.26

Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

31 March 2020

1 reference

12 December 2020

Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

1 reference

12 December 2020

Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase).

1 reference

12 December 2020

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

1 reference

12 December 2020

Guideline for the management of clinically localized prostate cancer: 2007 update.

1 reference

12 December 2020

Prostate-specific membrane antigen expression in normal and malignant human tissues

1 reference

12 December 2020

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

1 reference

12 December 2020

Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain.

1 reference

12 December 2020

Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line

1 reference

12 December 2020

Prostate-specific membrane antigen is produced in tumor-associated neovasculature

1 reference

12 December 2020

Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

1 reference

12 December 2020

Overview of prostate-specific membrane antigen

1 reference

12 December 2020

Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2016.26

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference